NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
BFN
Jefferies International today reaffirms its hold investment rating on NMC Health PLC (LON:NMC) and raised its price target to 3291p (from 3085p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

Agreement
RNS
RNS Number : 8587Q
NMC Health Plc
11 June 2018

11 June 2018

NMC Health plc
(the "Company" or "NMC")

NMC enters into a transformational partnership with Hassana Investment Company to create a new healthcare platform in Kingdom of Saudi Arabia


NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international operations across 13 countries, is pleased to announce the signing of a non-binding agreement to form a joint-venture healthcare platform with Hassana Investment Company ("Hassana"), the investment arm of the General Organization for Social Insurance ("GOSI"), which is the largest pension fund in Kingdom of Saudi Arabia ("KSA").

· Proposed formation of a new national healthcare company, pursuing a unique strategy in KSA
· JV to be formed through contribution of existing assets by both NMC and GOSI's investment in Tadawul-listed National Medical Care Company ("CARE")
· At inception, the platform would be one of the largest private healthcare operator in KSA by beds capacity
· NMC and Hassana have ambitious plans to expand and benefit from the strong growth potential of the healthcare sector in KSA through the proposed entity
· GOSI would continue to own a significant indirect stake in CARE through this proposed JV
· The proposed partnership would drive NMC's strong expansion in the KSA healthcare market


Larger platform to deliver more efficient deployment of capital in KSA

The proposed JV would create one of the largest private healthcare platforms operating in KSA today. The JV would have a strategically unique position in the country, with a strong foothold in Riyadh, the single largest healthcare market in KSA, as well as in multiple smaller, underserved cities. The enlarged organization is expected to benefit from economies of scale, allowing more efficient deployment of capital, increasing patient choice and optimizing returns across multiple assets. Furthermore, in-line with NMC's existing strategy, the proposed JV platform would continue to build a strong pan-KSA presence, unlocking considerable synergies across its facilities in the process. These are expected to cover business segments such as revenue cycle management, procurement, HR and IT systems among others.

Key terms of the agreement

· GoSI/ Hassana will transfer their 38.9% stake in CARE at a price of SAR 70/share, implying an attractive 2018E EV/EBITDA multiple of less than 15x
· NMC will contribute all of its existing KSA-based assets as part of the formation of the JV platform
· Under the terms of the agreement, there will be revaluation of NMC's assets, representing considerable value accretion at the joint-venture as well as NMC Health plc level
· The JV will have a combined bed capacity of 1,489 (664 beds contributed by NMC and 825 by CARE)
· Formation of the JV is subject to regulatory approvals and signing of definitive agreements after completion of necessary due diligence by both the parties
· For the year ended 31 December 2017, NMC reported gross assets of US$3.0 billion and profits before tax of US$210.4 million. For the same period, CARE reported gross assets of US$380.0 million and profits before tax of US$26.7 million


NMC will retain a majority stake, as well as operational control, in the JV

NMC will hold a voting majority in the proposed JV, with the exact stake subject to final terms. Consequently, NMC will fully consolidate the JV financials. NMC will also retain operational and management control of the assets held by the JV.

The proposed JV platform will serve as the main vehicle of future expansion for NMC in KSA. The proposed JV will seek to take majority, as well as minority, stakes in KSA-based healthcare operators (organic and inorganic investments), along with acquiring O&M contracts to manage private and government sector hospitals in the country.

The JV platform is expected to benefit significantly from NMC's operational expertise in the healthcare sector, as well as Hassana's local market knowledge and strategic position as a long term financial investor. The formation of this platform represents the strong commitment by both NMC and Hassana towards the KSA healthcare market.

Prasanth Manghat, Chief Executive Officer of NMC, commented:

"We identified KSA as a key strategic priority for NMC and the proposed partnership between NMC and GoSI/ Hassana would offer a tremendous opportunity for both the companies to better serve the KSA healthcare market. The Saudi government's forward looking and investor friendly policies make the Kingdom one of the most attractive destinations in the region for investment in the healthcare sector. Moreover, Hassana's strong commitment to the sector, particularly in the form of strategic investments, remains a vital means of attracting and developing healthcare expertise in the country. NMC has been the most progressive foreign entrant in the Saudi healthcare market, and the proposed partnership with Hassana would accelerate the process of bringing international best practices to KSA. In addition to being ideally positioned to participate in the highly anticipated privatization program in KSA, the proposed JV platform will continue to fill service gaps in the market. This is expected to be achieved through a wide range of means, be it through the development of IVF, long-term care and cosmetics segments or the introduction of pediatric centers of excellence and state-of-the-art cancer centers."

Saad bin Abdulmohsen Al-Fadly, Chief Executive Officer of Hassana, commented:

"The proposed partnership between Hassana and NMC is driven by our view that healthcare in Saudi Arabia is one of the most attractive markets for strong long-term growth. The proposed JV has ambitious growth plans across different healthcare sub-sectors, with both partners committed to compounding returns over the long-term, whilst providing best-of-class services to patients. Benefiting from Hassana's role as a strong long term financial and strategic investor and NMC's expertise as a sophisticated and successful healthcare expert in the region, the JV platform would be well-positioned to become one of the most dominant healthcare players in Saudi Arabia and is ideally positioned to capitalize on the health care privatization program in Saudi Arabia in line with the country's Vision 2030 initiatives."

08:10 07/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its overweight investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 4250p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Business Update
RNS
RNS Number : 2230Y
NMC Health Plc
20 August 2018

20 August 2018

NMC Health plc
(the "Company" or "NMC")

Continuous execution of 2017 enhanced strategy

Further geographic expansion of the IVF platform: Extending foothold in Europe and entry into the African market

First O&M contract signed in sub-Saharan Africa

UK acquisition reinforces capability enhancement program

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces significant progress the Company has made during 2018 against the updated strategy announced in December 2017.

Development of Centers of Excellence as potential verticals

With the verticals-based structure serving NMC well across its rapid growth, the Company continues to evaluate potential new additions to the framework. As highlighted previously, the recently acquired cosmetics business represents a strong candidate in this regard. Additionally, NMC's Pediatric Centre of Excellence is rapidly emerging as a potential new, organically grown vertical. The Company has significantly enhanced the quality and complexity of pediatric care in the UAE following its collaboration with Cincinnati Children's Hospital, one of the top two children-focused hospitals in the US. Under the terms of the agreement, key child specialists from the American hospital visit NMC Royal hospital on a periodic basis, bringing previously unavailable medical services in the country. Given the shortage of pediatric healthcare services in the GCC in general and the UAE in particular, this segment represents strong potential for growth, and hence an upgrade to a vertical status.

While the abovementioned offer the nearest term potential to form new verticals, management continues to see promise across a number of other Centers of Excellence that could eventually become independent verticals as well. The most prominent among these include Orthopedics, Cardiology, Oncology and Ophthalmology.

Expanding healthcare business target market from GCC to wider Emerging Markets

NMC's Operations & Management (O&M) vertical continues to serve as a risk-controlled means of gaining exposure to new markets outside the GCC and evaluating opportunities for capital deployment. Following the Egyptian O&M contracts announced in January 2018, NMC has now extended its reach to sub-Saharan Africa through signing of O&M contracts with private parties in Kenya. Signed on 1 July 2018, the contracts cover two hospitals in Nairobi and will generate revenues of US$2m per annum. Additionally, the Kenyan government has requested NMC to advise on affordable healthcare technology for school going students.

In addition to high margin revenues, the O&M contracts are expected to provide considerable cross referral opportunities to NMC's UAE-based facilities. Kenya, as well as the wider sub-Saharan Africa, remains an important source of medical tourism to the UAE due to its geographic proximity and conducive visa regulations.

Extending the IVF global footprint

Highlighted during the 2017 strategy update as a truly global opportunity, NMC's IVF business continues to extend its international reach, with three new markets added recently including Sweden, Latvia and Kenya. The Company has acquired leading IVF clinics in Sweden and Latvia, broadening its foothold in the attractive European market for a combined consideration of c. US $25m. In addition to being value accretive acquisitions (both transactions completed at multiples below 8x 2018E EV/EBITDA), these top-rated clinics add substantial research expertise in the Fertility segment. They also bring highly experienced doctors to NMC's team, including world renowned gynecologist, Dr. Mats Brännström, who made history by successfully conducting the world's first uterus transplant.

Moreover, adding a fourth continent in the form of Africa, NMC's Fertility business has entered the Kenyan market through a Greenfield expansion in Nairobi. Fully integrated with our European brand, Clinica Eugin, the clinic will be the only global platform in Africa. Infertility represents a major reproductive health problem across Africa in general and in sub-Saharan Africa in particular. Given its solid expertise in Europe, in-house resources, operational expertise and research capabilities, NMC is ideally positioned to invest in this developing market. With the Kenyan facility expected to attract patients from adjoining East African markets of Tanzania, Uganda and Rwanda, NMC views its state-of-the-art clinic as a launchpad for the attractive African market.

Acquisition of UK-based Aspen Healthcare: Establishing Centers of Excellence in GCC with capability enhancement program

NMC has acquired 100% of the equity of Aspen Healthcare ("Aspen") from Tenet Healthcare for an Enterprise Value of GBP 10m. Aspen operates a network of nine facilities across the UK including four hospitals, three of which are based in Greater London (Parkside Hospital, The Holly Private Hospital and Highgate Hospital).

Aspen facilities provide quality services, with NHS accounting for less than 30% of revenues. While offering a large range of specialties, Aspen is particularly recognized in Orthopedics and Oncology, which represent 50% of the company's revenues. Both segments remain highly underserved in the UAE, thus offering the dual benefit of knowledge transfer as well as potential for patient referral to NMC's own international facilities when the required medical treatment is unavailable in the country.

The acquisition also provides NMC a very cost-effective means of introducing its fertility services to the UK. Situated in prime locations, the facilities have the required civil structures in place for rapid deployment of our world-renowned IVF services.

NMC's management sees significant opportunity for driving margin and earnings growth at the newly acquired facilities. However, while capital expenditure is planned for the Aspen facilities, NMC does not currently intend to invest in other non-fertility based healthcare facilities in the UK.

NMC intends to finance the transaction using existing cash resources. For the year ended 31 December 2017, Aspen reported EBITDA of £5m (US$7m) and had gross assets of £173m (US$221m). The transaction is expected to be neutral to NMC's EPS in 2018.

Adapting to rapid technological developments in the healthcare sector

NMC is ardently keeping an eye on global digital health trends, such as mobile health, artificial intelligence enabled healthcare platforms, genomics and robotics. These developments are expected to have a dramatic impact on healthcare delivery in the coming years. NMC is exploring novel ways to collaborate with industry leaders in these technological fields to pioneer a futuristic healthcare value chain to improve accessibility, enhancing clinical outcomes and reducing costs.

Mr Prasanth Manghat, Chief Executive Officer, commented:

"In December 2017, we set out our new strategy to drive future growth by focusing on leveraging our healthcare services expertise to increase capacity, growing our capabilities and expanding across multiple geographies. Our flexible model allows us to consider opportunities to manage as well as own healthcare facilities. We continue to expand into new geographies, with our footprint now spread across 17 countries. Despite the passage of a relatively short time period since outlining the enhanced strategy, we have made substantial progress across all facets. We continue to strengthen NMC's reputation as a provider of world class services for our patients and are cementing our position as a leading global healthcare operator."

Half year report part1

H1 2018 Group financial highlights

· Group reported revenues increased by 20.2% YoY to US$932.0m, with organic growth accounting for 13.4% of this growth
· EBITDA margin increased by 220bps to 24.2% as EBITDA growth (+32.1% to US$225.5m) continues to outpace revenue growth
· Financial and operational performance during H1 2018 remained in line with expectations, with management maintaining positive outlook for H2 2018

Half year report part2

Broker Forecast - JP Morgan Cazenove issues a broker note on NMC Health PLC
BFN
JP Morgan Cazenove today reaffirms its neutral investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4060p (from 3270p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

10:00 22/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its top pick investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4850p (from 4600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

21 Sep
Barclays...
N/A
Overweight
22 Aug
Barclays...
4,850.00
Top pick

i hold a few of these in my sipp, and thus with a fairly long term view
it's certainly a dangerous stock to try to trade as the chart shows, for it can be horribly volatile for no apparent reason

There was another UAE hospital/ health care provider I opened a thread for at the same time. I think they changed the company name, but this one has out performed it. Yes can be volatile.

Mediclinic International Plc (MDC) found it.

Not sure you will have heard of this company dream , but it has promise , it's called Versarien , AGM on Tues 25th , keep it to yourself as it could rocket soon .

Who are they? I hope you filled your boots on the normal pullback.

Suppose I should have learnt that by now , I'll have to get into this profit taking mentality , see it's on it's way back up now , it's the fear of news coming pre agm .

Playing with all profit only now, Which we all must have a very good balance. :-))

Going to be an interesting afternoon. Hold your hats on.lol

Capital Markets Day & Positively Revised Guidance
RNS
RNS Number : 6831E
NMC Health Plc
22 October 2018

22 October 2018

NMC Health plc
(the "Company" or "NMC")

Capital Markets Day and Positively Revised Guidance

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces that the Company will be holding a Capital Markets Day today at the London Stock Exchange.

Prashanth Shenoy, Chief Financial Officer of NMC Health, will provide an update on guidance given in January, following positive developments in the second half of 2018. As a result, we now anticipate an increase of 2% in revenue growth from 22% to 24% and an increased EBITDA guidance from $465m to $480m by year-end 2018.

2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance. Revenues are forecast to increase by 22-24% and EBITDA is expected to increase by 18-20%. 2019 guidance does not include the effects of implementation of IFRS 16. The guidance also does not reflect the impact of anticipated financial consolidation of National Medical Care Company. An update in this regard will be provided once the joint-venture with Hassana/GOSI has been formalized, which is on track for completion during Q4 18.

During the year 2019, management also anticipates: 1) opening of new greenfield facilities, particularly in UAE, 2) continued ramp-up of various facilities across multiple geographies and 3) full-year consolidation of Aspen Healthcare, all of which will impact EBITDA margin.

Management remains confident on the longer-term margin guidance for the Company and NMC remains on track to achieve 25% EBITDA margin by 2020/2021.

10:00 23/10/2018
Broker Forecast - HSBC issues a broker note on NMC Health PLC
HSBC today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 1430p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Purchase of Shares
RNS
RNS Number : 8923F
NMC Health Plc
31 October 2018



NMC Health plc

Purchase of Shares


London, 31 October 2018: NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, received notification from Jonathan Bomford, the Senior Independent Director of the Company, that on 31 October 2018 he bought through his SIPP, 1,000 ordinary shares of 10p each in the Company ("Shares") at a price of 3475.545p pence per share.

Following this transaction, Jonathan Bomford's share interest, including the shares held by his spouse, has increased to 20,000 Shares, representing approximately 0.01% of the issued share capital of the Company.